The study will evaluate M118, a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS). M118 will also be tested for its tolerability and pharmacokinetic profile.
In preclinical studies, M118 has been shown to be at least as effective as unfractionated heparin in inhibiting clot formation without causing increased bleeding complications.
“Our preclinical studies have shown that M118 could be a potent agent that provides consistent, flexible and reversible anticoagulant therapy. We believe that M118 has the opportunity to be a future baseline anticoagulant therapy for ACS patients.” said Craig Wheeler, President and CEO of Momenta “We see great promise for further application of our technology to design other novel heparin and protein-based therapies.”
Momenta expects to have preliminary results from this study in the first half of 2007.